AACR Adds to Growing STAR P-2 trial; Publishes Update and Perspectives in Cancer Prevention Research

As part of its continuing commitment to prevention research, the AACR published the full STAR P-2 study along with an update and several Perspectives from leaders in the field exploring its implications in the June issue of Cancer Prevention Research.

Philadelphia, PA (Vocus) June 4, 2010

As part of its continuing commitment to prevention research, the AACR published the full STAR P-2 study along with an update and several Perspectives from leaders in the field exploring its implications in the June issue of Cancer Prevention Research.

This past April, during the American Association for Cancer Research 101st Annual Meeting 2010 in Washington, D.C., Larry Wickerham, M.D., presented the results of the STAR P-2 trial, which definitively showed raloxifene as a suitable alternative to tamoxifen in the chemoprevention of breast cancer among high-risk women.

As part of its continuing commitment to prevention research, the AACR published the full STAR P-2 study along with an update and several Perspectives from leaders in the field exploring its implications in the June issue of Cancer Prevention Research. Read the study, update and Perspectives to learn more. Also watch Dr. Wickerham’s presentation from the Annual Meeting and listen to the AACR STAR P-2 trial press conference featuring leading researchers and patient advocates.

###


Contact